University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Harold Collard, M.D.

Director of the Interstitial Lung Disease Program

Dr. Harold R. Collard is an assistant professor of medicine in the Division of Pulmonary and Critical Care Medicine and the director of the Interstitial Lung Disease Program at UCSF Medical Center. His primary interest is in the management of patients with interstitial lung disease, including how best to diagnose and treat interstitial lung disease and how the condition impacts a patient's quality of life and survival.

Collard earned a medical degree at Duke University. He completed an internship, residency and chief residency in internal medicine at UCSF as well as a fellowship in pulmonary and critical care medicine at the University of Colorado. Prior to joining UCSF, Collard was a member of the Interstitial Lung Disease Program at the National Jewish Medical and Research Center in Denver.

Clinics

Interstitial Lung Disease Program
400 Parnassus Ave., Fifth Floor
San Francisco, CA 94143
Phone: (415) 353-2577
Fax: (415) 353-2568

Hours: Friday
8 a.m. – noon

Pulmonary Practice at Parnassus
400 Parnassus Ave., Fifth Floor
San Francisco, CA 94143-0359
Phone: (415) 353-2961
Fax: (415) 353-2568

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

More about Harold Collard

Education

Duke University School of Medicine 1997

Residencies

UCSF Medical Center, Internal Medicine 2000

Fellowships

University of Colorado Medical Center 2004

Selected Research and Publications

  1. Corte TJ, Collard H, Wells AU. Idiopathic interstitial pneumonias in 2015: A new era. Respirology. 2015 Jul; 20(5):697-8.
  2. Collard HR. Where do we go from here? Clinical drug development in idiopathic pulmonary fibrosis. Eur Respir J. 2015 May; 45(5):1218-20.
  3. Collard HR, Bradford WZ, Cottin V, Flaherty KR, King TE, Koch GG, Kolb M, Martinez FJ, Montgomery B, Raghu G, Richeldi L, Rose D, Wells AU, Brown KK. A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. Eur Respir J. 2015 Jul; 46(1):243-9.
  4. Durheim MT, Collard HR, Roberts RS, Brown KK, Flaherty KR, King TE, Palmer SM, Raghu G, Snyder LD, Anstrom KJ, Martinez FJ. Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. Lancet Respir Med. 2015 May; 3(5):388-96.
  5. Johannson KA, Balmes JR, Collard HR. Air pollution exposure: a novel environmental risk factor for interstitial lung disease? Chest. 2015 Apr 1; 147(4):1161-7.
  6. Ley B, Bradford WZ, Weycker D, Vittinghoff E, du Bois RM, Collard HR. Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis. Eur Respir J. 2015 Jan 22.
  7. Collard HR, Brown KK, Martinez FJ, Raghu G, Roberts RS, Anstrom KJ. Study design implications of death and hospitalization as end points in idiopathic pulmonary fibrosis. Chest. 2014 Nov 1; 146(5):1256-62.
  8. White ES, Brown KK, Collard HR, Conoscenti CS, Cosgrove GP, Flaherty KR, Leff JA, Martinez FJ, Roman J, Rose D, Violette S, Kaminski N. Open-access biorepository for idiopathic pulmonary fibrosis. The way forward. Ann Am Thorac Soc. 2014 Oct; 11(8):1171-5.
  9. Ley B, Brown KK, Collard HR. Molecular biomarkers in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2014 Nov 1; 307(9):L681-91.
  10. DePianto DJ, Chandriani S, Abbas AR, Jia G, N'Diaye EN, Caplazi P, Kauder SE, Biswas S, Karnik SK, Ha C, Modrusan Z, Matthay MA, Kukreja J, Collard HR, Egen JG, Wolters PJ, Arron JR. Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis. Thorax. 2015 Jan; 70(1):48-56.
  11. Ryerson CJ, Collard HR. Acute exacerbations complicating interstitial lung disease. Curr Opin Pulm Med. 2014 Sep; 20(5):436-41.
  12. Ryerson CJ, Corte TJ, Collard HR, Richeldi L. A global registry for idiopathic pulmonary fibrosis: the time is now. Eur Respir J. 2014 Aug; 44(2):273-6.
  13. Winstone TA, Assayag D, Wilcox PG, Dunne JV, Hague CJ, Leipsic J, Collard HR, Ryerson CJ. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest. 2014 Aug; 146(2):422-36.
  14. Ryerson CJ, Collard HR. Hot off the breath: A big step forward for idiopathic pulmonary fibrosis. Thorax. 2014 Sep; 69(9):791-2.
  15. Stuart BD, Lee JS, Kozlitina J, Noth I, Devine MS, Glazer CS, Torres F, Kaza V, Girod CE, Jones KD, Elicker BM, Ma SF, Vij R, Collard HR, Wolters PJ, Garcia CK. Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation. Lancet Respir Med. 2014 Jul; 2(7):557-65.
  16. Ley B, Elicker BM, Hartman TE, Ryerson CJ, Vittinghoff E, Ryu JH, Lee JS, Jones KD, Richeldi L, King TE, Collard HR. Idiopathic pulmonary fibrosis: CT and risk of death. Radiology. 2014 Nov; 273(2):570-9.
  17. Lubin M, Chen H, Elicker B, Jones KD, Collard HR, Lee JS. A comparison of health-related quality of life in idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. Chest. 2014 Jun; 145(6):1333-8.
  18. Kolb M, Collard HR. Staging of idiopathic pulmonary fibrosis: past, present and future. Eur Respir Rev. 2014 Jun; 23(132):220-4.
  19. Chandriani S, DePianto DJ, N'Diaye EN, Abbas AR, Jackman J, Bevers J, Ramirez-Carrozzi V, Pappu R, Kauder SE, Toy K, Ha C, Modrusan Z, Wu LC, Collard HR, Wolters PJ, Egen JG, Arron JR. Endogenously expressed IL-13Ra2 attenuates IL-13-mediated responses but does not activate signaling in human lung fibroblasts. J Immunol. 2014 Jul 1; 193(1):111-9.
  20. Raghu G, Chen SY, Yeh WS, Maroni B, Li Q, Lee YC, Collard HR. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med. 2014 Jul; 2(7):566-72.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.